Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations - 08/06/20
, Neha J. Pajidipati, MD a, b, Robert W. McGarrah, MD a, c, Ann Marie Navar, MD, PhD a, b, Sreekanth Vemulapalli, MD a, b, Michael A. Blazing, MD a, Svati H. Shah, MD, MHS a, b, c, Adrian F. Hernandez, MD a, b, Manesh R. Patel, MD a, bRésumé |
Lipoprotein (a) [Lp(a)] is a low-density, cholesterol-containing lipoprotein that differs from other low-density lipoproteins due to the presence of apolipoprotein(a) bound to its surface apolipoprotein B100. Multiple epidemiologic studies, including Mendelian Randomization studies, have demonstrated that increasing Lp(a) levels are associated with increased risk of heart disease, including atherosclerotic cardiovascular disease and calcific aortic stenosis. The risk associated with elevations in Lp(a) appears to be independent of other lipid markers. While the current treatment options for elevated Lp(a) are limited, promising new therapies are under development, leading to renewed interest in Lp(a). This review provides an overview of the biology and epidemiology of Lp(a), available outcome studies, and insights into future therapies.
Le texte complet de cet article est disponible en PDF.Plan
Vol 126
P. 94-102 - juillet 2020 Retour au numéro
Article précédent
- Long-Term Outcome of Pericardial Drainage in Cases of Chronic, Large, Hemodynamically Insignificant, C-Reactive Protein Negative, Idiopathic Pericardial Effusions
- George Lazaros, Alexios S. Antonopoulos, Emilia Lazarou, Charalambos Vlachopoulos, Emmanuel Foukarakis, Aristides Androulakis, Athanasios Manginas, Kalos Theodoros, Apostolos Karavidas, Dimitris Tousoulis
- Collectables: Part I of II
- Robert M. Doroghazi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?